The research company Mendus reports preliminary data from the CADENCE and VITAL-CML studies showing that vididencel activates multiple components of the immune system.
The results are based on samples from 13 and 7 patients, respectively, and support previous observations from ADVANCE II and ALISON. In VITAL-CML, no sustained improvement in the molecular response has yet been demonstrated.
Longer follow-up is required to assess the treatment’s effect on the disease.
Initial efficacy data from CADENCE are expected in the first half of 2027 and topline data from VITAL-CML in mid-2027.
